Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

(2015) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma

(2015) E. Wilson Grandin et al.   JOURNAL OF CARDIAC FAILURE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib-induced acute congestive heart failure: a case report and review of literature

(2014) Ashish Subedi et al.   ANNALS OF HEMATOLOGY

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database

(2013) Benjamin Honton et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

(2012) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

(2010) Dominika Nowis et al.   AMERICAN JOURNAL OF PATHOLOGY